Bharat Biotech International Limited Chairman Dr Krishna Ella on Monday said today's neglected infectious diseases could be tomorrow's global pandemic and stressed the need to have a coherent strategy to fight them.
He said this during an event organised as part of the 38 foundation day celebrations by CSIR-Institute of Microbial Technology (IMTECH), Chandigarh.
Bharat Biotech's Covaxin is credited to be India's first indigenous COVID-19 vaccine to be approved and administered to a sizeable population across the globe.
Delivering this year's foundation day lecture virtually on Innovation and Leadership in Pandemic, Ella highlighted how today's neglected infectious diseases could be tomorrow's global pandemic and stressed the need to have a coherent strategy to fight infectious diseases, according to an CSIR-IMTECH statement.
During his lecture, Dr Ella highlighted how innovative technology in vaccine development is essential to solve public healthcare problems caused by infectious diseases.
He said Indian pharmaceutical companies need to innovate beyond generic vaccines to be a global player in the vaccine market.
He stressed the need for scientists to examine the unknowns that could be the future cause of pandemic through zoonotic and unknown viruses.
A serial entrepreneur with a passion for innovative ideas, Bharat Biotech has also ventured into veterinary vaccines, food processing, and developing biotechnology infrastructure in the country.
Dr Ella is also involved in shaping India's science education and policy through his association with several committees, said the statement.
Dr Shekhar C Mande, Secretary, Department of Scientific and Industrial Research & Director General CSIR, asked scientists to focus on microbiome therapies, which could be future game changer for treating diseases.
Dr Sanjeev Khosla, Director, CSIR-IMTECH, lauded efforts of scientists and researchers for the work carried out to fight the pandemic during the challenging times of COVID-19.
The CSIR-IMTECH is a national centre for excellence in microbial sciences and was established in 1984.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)